NCOA3 Fusion

CI-VAR-00001494Explore in graph →CIViC 5343

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Uterine Neoplasm2
ESR1::NCOA3 Fusion OR ESR1::NCOA2 Fusion OR GREB1::NCOA2 Fusion	(diagnostic)	Diagnostic	C	Supports Positive	2	submitted	EID12701 In uterine tumors resembling ovarian sex cord tumor (UTROSCT; n = 4), RNA sequencing identified recurrent ESR1::NCOA3 (n = 2), ESR1::NCOA2 (n = 1), and GREB1::NCOA2 (n = 1) fusions, involving NCOA2/3 … (full text at CIViC) PMID 30273195 · Dickson et al., 2019 · Open in CIViC	civic
ESR1::NCOA3 Fusion OR GREB1::NCOA2 Fusion OR ESR1::CITED2 Fusion OR ESR1::v Fusion OR GREB1::v Fusion	(prognostic)	Prognostic	C	Supports Poor Outcome	1	submitted	EID12707 In a retrospective UTROSCT cohort (n = 17, follow-up n = 13), 3 patients (23.1%) carrying GREB1::NCOA2, ESR1::NCOA3 or ESR1::CITED2 fusions developed pelvic, abdominal or pulmonary recurrence, with re… (full text at CIViC) PMID 38000680 · Qijun et al., 2024 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.